ReviewFrontiers in immunology2026
Mechano-metabolic coupling in the tumor microenvironment: from mechanotransduction to protein lactylation and metastatic cascades.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aberrant mechanical signals within the tumor microenvironment (TME)-including increased extracellular matrix stiffness, elevated solid stress, heightened interstitial fluid pressure, and fluid shear stress-have been established as key drivers of malignant tumor progression and metastasis. These physical cues are sensed by mechanoreceptors on the cell membrane (Piezo1, TRP channels, and integrin-FAK complexes), transmitted intracellularly through Rho GTPases and cytoskeletal dynamics, and ultimately reprogram transcriptional programs via nuclear translocation of transcriptional co-activators such as YAP/TAZ. Mechanical signals also drive metabolic reprogramming in tumor cells, particularly enhancing aerobic glycolysis (the Warburg effect), which results in massive lactate accumulation. Landmark discoveries in recent years have revealed that lactate serves as a substrate to drive histone and non-histone lactylation, directly coupling metabolic status with epigenetic regulation. Histone lactylation (e.g., H3K18la, H3K9la) activates pro-metastatic transcriptional programs by remodeling chromatin accessibility, promoting epithelial-mesenchymal transition (EMT), immune evasion, and therapeutic resistance; non-histone lactylation directly modifies cytoskeletal proteins (CFL1, vimentin, TPX2) and transcriptional regulators (Snail, YY1, PRMT1), enhancing the metastatic execution capacity of tumor cells at multiple levels, including cellular mechanical properties, migratory ability, and signal transduction. Importantly, mechanical signals, metabolic reprogramming, and lactylation constitute a mechano-metabolism-lactylation positive feedback loop, forming a self-reinforcing vicious cycle that continuously fuels tumor metastasis. This review systematically outlines the types and mechanotransduction mechanisms of TME mechanical signals, mechanically driven metabolic and transcriptional reprogramming, the multifaceted functions of lactylation in tumor metastasis, and the ultimate execution of the metastatic cascade driven by this positive feedback loop, and discusses potential therapeutic strategies targeting mechanosensitive pathways, metabolic vulnerabilities, and lactylation-modifying enzymes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.